Trial · NCT00875836
Buspirone Treatment for Marijuana Dependence
NCT00875836, Phase 4, Completed, Medical University of South Carolina; results first posted 2016-03-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Buspirone Treatment for Marijuana Dependence. Trials, record NCT00875836. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00875836
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Buspirone Treatment for Marijuana Dependence
- NCT number
- NCT00875836
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 175 participants, actual
- Lead sponsor
- Medical University of South Carolina
- Conditions
- Marijuana Dependence
- Interventions
- Buspirone, Placebo
- First posted
- 2009-04-03
- Last updated
- 2016-08-10
- Results first posted
- 2016-03-09
- Limitations and caveats
Limitations included significant attrition during the course of the 12-week trial, difficulty with UCT interpretation due to the long excretion half-life of marijuana in urine, and likelihood that the genetic analysis was underpowered.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Marijuana-negative Urine Drug Screens (UDS) | Participants provided a once-weekly urine sample for twelve weeks | Participants submitted a urine sample weekly. Percentage of marijuana negative urine samples were calculated per group. |
| Secondary | Retention in the Study | participants were followed for twelve weeks | Number of days subjects remained active in the study |
| Secondary | Marijuana Craving | 8 Weeks | The Marijuana Craving Questionnaire (MCQ) is intended to measure marijuana craving in adults. It measures symptoms on four subscales: expectancy, purposefulness, emotionality, and compulsivity. The scale rates individual items from 1 (least craving) - 7 (most craving) with a composite scoring range of 12-84 and possible subscale scoring range of 3-21. It was administered weekly- reported here is the mean composite score across the 8 week treatment course. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Marijuana-negative Urine Drug Screens (UDS) | Participants provided a once-weekly urine sample for twelve weeks | percentage of UDS | NUMBER | |
| SECONDARY | Retention in the Study | participants were followed for twelve weeks | Day | MEDIAN | |
| SECONDARY | Marijuana Craving | 8 Weeks | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Marijuana-negative Urine Drug Screens (UDS) | Buspirone | 7.2 | percentage of UDS | ||
| Percent Marijuana-negative Urine Drug Screens (UDS) | Placebo | 6.4 | percentage of UDS | ||
| Retention in the Study | Buspirone | 79 | Inter-Quartile Range 18 to 91 | Day | |
| Retention in the Study | Placebo | 84 | Inter-Quartile Range 14 to 91 | Day | |
| Marijuana Craving | Buspirone | 29.6 | 95% Confidence Interval 27.0 to 32.2 | units on a scale | |
| Marijuana Craving | Placebo | 28.4 | 95% Confidence Interval 25.8 to 31.1 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Buspirone | 88 | |
| Overall Study | STARTED | Placebo | 87 | |
| Overall Study | COMPLETED | Buspirone | 45 | |
| Overall Study | COMPLETED | Placebo | 47 | |
| Overall Study | NOT COMPLETED | Buspirone | 43 | |
| Overall Study | NOT COMPLETED | Placebo | 40 |
Source ClinicalTrials.gov
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anxiety or Depression | Psychiatric disorders | Buspirone | 4 | 88 | 5 |
| other | Anxiety or Depression | Psychiatric disorders | Placebo | 5 | 87 | 5 |
| other | Dizziness or lightheaded | Nervous system disorders | Buspirone | 36 | 88 | 44 |
| other | Dizziness or lightheaded | Nervous system disorders | Placebo | 11 | 87 | 17 |
| other | Drowsiness | Nervous system disorders | Buspirone | 17 | 88 | 19 |
| other | Drowsiness | Nervous system disorders | Placebo | 15 | 87 | 18 |
| other | Gastrointestinal | Gastrointestinal disorders | Buspirone | 36 | 88 | 61 |
| other | Gastrointestinal | Gastrointestinal disorders | Placebo | 23 | 87 | 35 |
| other | Headache | Nervous system disorders | Buspirone | 28 | 88 | 55 |
| other | Headache | Nervous system disorders | Placebo | 27 | 87 | 46 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Buspirone | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Buspirone | 73 | 88 |
| Total, other adverse events | Placebo | 66 | 87 |
| Total, serious adverse events | Buspirone | 0 | 88 |
| Total, serious adverse events | Placebo | 0 | 87 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA026782 | Buspirone Treatment for Marijuana Dependence | MCRAE-CLARK, AIMEE L | MEDICAL UNIVERSITY OF SOUTH CAROLINA | NATIONAL INSTITUTE ON DRUG ABUSE | 2009 to 2013 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Buspirone vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00875836
GET https://conductscience.org/api/trials/v1/NCT00875836/registered